2868 related articles for article (PubMed ID: 33426371)
1. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
2. Biological drug and drug delivery-mediated immunotherapy.
Xiao Q; Li X; Li Y; Wu Z; Xu C; Chen Z; He W
Acta Pharm Sin B; 2021 Apr; 11(4):941-960. PubMed ID: 33996408
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of natural products in cancer immunotherapy.
Dong S; Guo X; Han F; He Z; Wang Y
Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
5. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
6. Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment.
Zhang M; Hu W; Cai C; Wu Y; Li J; Dong S
Mater Today Bio; 2022 Mar; 14():100223. PubMed ID: 35243298
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy.
Qiu Q; Li C; Song Y; Shi T; Luo X; Zhang H; Hu L; Yan X; Zheng H; Liu M; Liu M; Liu M; Yang S; Liu X; Chen G; Deng Y
Acta Biomater; 2019 Jul; 92():184-195. PubMed ID: 31108259
[TBL] [Abstract][Full Text] [Related]
8. Biomacromolecules as carriers in drug delivery and tissue engineering.
Zhang Y; Sun T; Jiang C
Acta Pharm Sin B; 2018 Jan; 8(1):34-50. PubMed ID: 29872621
[TBL] [Abstract][Full Text] [Related]
9. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal.
Eljack S; David S; Faggad A; Chourpa I; Allard-Vannier E
Int J Pharm X; 2022 Dec; 4():100126. PubMed ID: 36147518
[TBL] [Abstract][Full Text] [Related]
11. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.
Draghiciu O; Lubbers J; Nijman HW; Daemen T
Oncoimmunology; 2015 Jan; 4(1):e954829. PubMed ID: 25949858
[TBL] [Abstract][Full Text] [Related]
12. Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment.
Zhang J; Fan J; Zeng X; Nie M; Luan J; Wang Y; Ju D; Yin K
Acta Pharm Sin B; 2021 Mar; 11(3):609-620. PubMed ID: 33777671
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design.
Qiao Q; Liu X; Yang T; Cui K; Kong L; Yang C; Zhang Z
Acta Pharm Sin B; 2021 Oct; 11(10):3060-3091. PubMed ID: 33977080
[TBL] [Abstract][Full Text] [Related]
14. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
15. Multitarget, multiagent PLGA nanoparticles for simultaneous tumor eradication and TME remodeling in a melanoma mouse model.
Ramzy A; Soliman AH; Hassanein SI; Sebak AA
Drug Deliv Transl Res; 2024 Feb; 14(2):491-509. PubMed ID: 37612575
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice.
Stamatopoulos A; Stamatopoulos T; Gamie Z; Kenanidis E; Ribeiro RDC; Rankin KS; Gerrand C; Dalgarno K; Tsiridis E
J Bone Oncol; 2019 Jun; 16():100231. PubMed ID: 30956944
[TBL] [Abstract][Full Text] [Related]
17. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
18. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
19. Cooperation of liver cells in health and disease.
Kmieć Z
Adv Anat Embryol Cell Biol; 2001; 161():III-XIII, 1-151. PubMed ID: 11729749
[TBL] [Abstract][Full Text] [Related]
20. Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy.
Heo MB; Kim SY; Yun WS; Lim YT
Int J Nanomedicine; 2015; 10():5981-92. PubMed ID: 26451105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
